Emelyanova MA, Ikonnikova AY. Utilization of molecular genetic approaches for colorectal cancer screening. World J Gastroenterol 2024; 30(46): 4950-4957 [DOI: 10.3748/wjg.v30.i46.4950]
Corresponding Author of This Article
Marina A Emelyanova, PhD, Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, No. 32 Vavilov Street, Moscow 119991, Russia. emel_marina@eimb.ru
Research Domain of This Article
Oncology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Dec 14, 2024; 30(46): 4950-4957 Published online Dec 14, 2024. doi: 10.3748/wjg.v30.i46.4950
Utilization of molecular genetic approaches for colorectal cancer screening
Marina A Emelyanova, Anna Y Ikonnikova
Marina A Emelyanova, Anna Y Ikonnikova, Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia
Author contributions: Emelyanova MA and Ikonnikova AY wrote and revised the manuscript; and all authors have read and approved the final manuscript.
Supported by the Ministry of Science and Higher Education of the Russian Federation to the EIMB Center for Precision Genome Editing and Genetic Technologies for Biomedicine Under the Federal Research Program for Genetic Technologies Development for 2019-2027, No. 075-15-2019-1660.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Marina A Emelyanova, PhD, Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, No. 32 Vavilov Street, Moscow 119991, Russia. emel_marina@eimb.ru
Received: July 22, 2024 Revised: October 14, 2024 Accepted: November 1, 2024 Published online: December 14, 2024 Processing time: 121 Days and 21 Hours
Abstract
The feasibility of population screening for colorectal cancer has been demonstrated in several studies. Most of these studies have considered individual characteristics, diagnostic approaches, epidemiological data, and socioeconomic factors. In this article, we comment on an editorial by Metaxas et al published in the recent issue of the journal. The authors emphasized the need to raise public awareness through health education programs and the possibility of using easily accessible non-invasive screening methods. Here, we focus on non-invasive molecular genetic approaches that can aid in colorectal cancer screening. On the one hand, we highlighted the use of tumor DNA/RNA markers directly for screening and, on the other hand, underline the use of polygenic risk assessment and hereditary predisposition to select individuals for more thorough cancer screening.
Core Tip: Despite the significant benefits of colorectal cancer (CRC) screening, current approaches need improvement. Here, we focus on molecular genetic techniques that may be useful in CRC screening. Their improvement and implementation are promising, on the one hand, due to their non-invasive nature, which enhances patient adherence to screening, and on the other hand, due to the personalization of screening programs based on an assessment of the individual risk of developing CRC.